Sagimet Biosciences Inc. (SGMT)
SGMT moved a median of +0.14% 30 minutes after news, and -0.52% by the close. How SGMT actually reacts to news — the realized, point-in-time move the market made, measured across 273 labeled events over the last three years with zero look-ahead.
SGMT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.23% | 54% | 273 |
| 30-min | +0.14% | 51% | 273 |
| 60-min | -0.50% | 45% | 273 |
| to close | -0.52% | 45% | 270 |
| Middle 50% of SGMT reactions | -2.00% to +2.98% |
|---|---|
| Median reaction (30-min) | +0.14% |
| Measured reactions | 273 |
Half of all Sagimet Biosciences Inc. news events land between -2.00% and +2.98% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SGMT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | -0.89% | 18% | -2.28% |
| Coverage initiations | 34 | +3.00% | 65% | +0.86% |
| Rating reiterations | 55 | 0.00% | 46% | +0.84% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how SGMT ranks against every other measured name →
That’s how SGMT usually reacts — get an email when it moves on news →Email me when SGMT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SGMT's baseline. Nothing else.
Recent SGMT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference | Press release | GlobeNewswire | -0.17% | +1.02% | |
| Form 8-K Sagimet Biosciences Inc. For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | +1.14% | -2.70% | |
| Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | +1.28% | -1.30% | |
| Form 8-K Sagimet Biosciences Inc. For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | -8.82% | -9.19% | |
| Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026 | Press release | GlobeNewswire | -8.82% | -9.19% | |
| Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -8.82% | -9.19% | |
| Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026 | Press release | GlobeNewswire | +0.44% | +8.63% | |
| Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences | Press release | GlobeNewswire | +3.04% | +4.57% | |
| Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026 | Press release | GlobeNewswire | +0.67% | -0.87% | |
| Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.40% | +1.63% | |
| Form 8-K Sagimet Biosciences Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +1.16% | -2.52% | |
| Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients | Press release | GlobeNewswire | +1.16% | -2.52% | |
| Form 10-Q Sagimet Biosciences Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.61% | -0.52% | |
| Form 8-K Sagimet Biosciences Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +2.61% | -0.52% | |
| Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | +2.61% | -0.52% | |
| Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference | Press release | GlobeNewswire | +4.13% | +11.75% | |
| Form 8-K Sagimet Biosciences Inc. For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | +0.35% | +0.14% | |
| Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes | Press release | GlobeNewswire | +1.08% | +11.77% | |
| Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +3.44% | +0.86% | |
| Form 8-K Sagimet Biosciences Inc. For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | +0.46% | -1.37% | |
| Form 8-K Sagimet Biosciences Inc. For: May 28 | SEC filing · Form 8-K | SEC EDGAR | +1.90% | +2.92% | |
| Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH | Press release | GlobeNewswire | +0.69% | +0.00% | |
| Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ | Press release | GlobeNewswire | +0.13% | -0.39% | |
| Form 10-Q Sagimet Biosciences Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.20% | +0.79% | |
| Form 8-K Sagimet Biosciences Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.20% | +0.79% | |
| Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | +0.20% | +0.79% | |
| Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago | Press release | GlobeNewswire | -0.07% | -0.13% | |
| Form 8-K Sagimet Biosciences Inc. For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | +6.54% | +4.79% | |
| Form 8-K Sagimet Biosciences Inc. For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | +10.11% | +12.46% | |
| Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock | Press release | GlobeNewswire | +10.11% | +12.46% | |
| Sagimet Biosciences Provides Strategic and Corporate Updates | Press release | GlobeNewswire | +10.11% | +12.46% | |
| Form 8-K Sagimet Biosciences Inc. For: Apr 20 | SEC filing · Form 8-K | SEC EDGAR | -3.07% | -9.22% | |
| Form ARS Sagimet Biosciences Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.27% | +3.80% | |
| Form DEF 14A Sagimet Biosciences Inc. For: Jun 12 | SEC filing · Form DEF | SEC EDGAR | +0.27% | +3.80% | |
| Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer | Press release | GlobeNewswire | -1.08% | -0.15% | |
| Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.19% | -3.20% | |
| Form 10-K Sagimet Biosciences Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.89% | -0.52% | |
| Form 8-K Sagimet Biosciences Inc. For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | +2.89% | -0.52% | |
| Form S-8 Sagimet Biosciences Inc. | SEC filing · Form S-8 | SEC EDGAR | +2.89% | -0.52% | |
| Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | +2.89% | -0.52% | |
| Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences | Press release | GlobeNewswire | +0.17% | +2.34% | |
| Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences | Press release | GlobeNewswire | -1.48% | -10.53% | |
| Form 8-K Sagimet Biosciences Inc. For: Feb 02 | SEC filing · Form 8-K | SEC EDGAR | -0.87% | +9.49% | |
| Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne | Press release | GlobeNewswire | -0.87% | +9.49% | |
| Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne | Press release | PR Newswire | -1.29% | -5.13% | |
| Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference | Press release | GlobeNewswire | +2.36% | +1.27% | |
| Form 8-K Sagimet Biosciences Inc. For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | +1.47% | -7.60% | |
| Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination | Press release | GlobeNewswire | +1.47% | -7.60% | |
| Form 8-K Sagimet Biosciences Inc. For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | +0.95% | -0.32% | |
| Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program | Press release | GlobeNewswire | +0.95% | -0.32% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SGMT section they belong to.
Where else SGMT is measured.
SGMT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Sagimet Biosciences Inc.'s median reaction calculated?
Every labeled SGMT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 273 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of SGMT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SGMT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.